response resistance mek inhibition leukaemias initiated hyperactive ras 
cascade comprising raf mitogen-activated protein kinase kinase mek extracellular signal-regulated kinase erk therapeutic target human cancers deregulated ras signalling includes tumours inactivated nf1 tumour suppressor12 nf1 encodes neurofibromin gtpase-activating protein terminates ras signalling stimulating hydrolysis ras-gtp compared effects inhibitors mek myeloproliferative disorder mpd initiated inactivating nf1 mouse bone marrow acute myeloid leukaemias amls cooperating mutations induced retroviral insertional mutagenesis show mek inhibitors ineffective mpd induce objective regression many nf1-deficient amls drug resistance developed outgrowth aml clones present treatment cloned clone-specific retroviral integrations identify candidate resistance genes including rasgrp1 rasgrp4 mapk14 encodes p38 alpha functional analysis implicated increased rasgrp1 levels reduced p38 kinase activity resistance mek inhibitors approach represents robust strategy identifying genes pathways modulate primary cancer cells respond targeted therapeutics probing mechanisms de novo acquired resistance 
